EXHIBIT  23.2


                       CONSENT OF INDEPENDENT ACCOUNTANTS




We  hereby  consent  to  the  incorporation  by  reference  in  the  Prospectus
constituting  part  of  the  Registration  Statement  on Form S-3 (No. 333-73125
pertaining  to  common  stock  issued  by Incyte Pharmaceuticals, Inc. to Former
Shareholders  of  Hexagen  Limited) and to the incorporation by reference in the
Registration  Statements on Form S-8 (Nos. 33-76236 and No. 33-93668  pertaining
to  the  1993 Directors' Stock Option Plan of Incyte Pharmaceuticals, Inc.; Nos.
33-76344,  33-93666,  333-13449,  333-31413 and 333-63069 pertaining to the 1991
Stock  Plan  of  Incyte  Pharmaceuticals,  Inc.; No. 333-31409 pertaining to the
Incyte  Pharmaceuticals,  Inc.  1997 Employee Stock Purchase Plan; No. 333-46639
pertaining  to  the  Options  Assumed by Incyte Pharmaceuticals, Inc. Originally
Granted  Under  the  Synteni, Inc. 1996 Equity Incentive Plan; and No. 333-67691
pertaining  to  Options  issued  by  Incyte  Pharmaceuticals,  Inc.  to  Former
Optionholders  of Hexagen Limited) of Incyte Pharmaceuticals, Inc. of our report
dated  January  15,  1999 relating to the financial statements of diaDexus, LLC,
appearing  on  page 67 of the Incyte Pharmaceuticals, Inc. Annual Report on Form
10-K  for  the  year  ended  December  31,  1998.

\s\  PricewaterhouseCoopers  LLP

San  Jose,  California
March  23,  1999